

## AGENDA

Day 1: Monday, 3<sup>rd</sup> October

- 11.00 Arrivals and Check-in
- 12.00-13.00 Lunch
- 13.00-13.10 Coordinator address
- 13.10-14.40 **WP1 Discovery of B cell specific therapeutic targets for CVD & WP2 Target Selection**  
Chair: Ignat Drozdov - Bering Limited, UK
- Targets from omics studies in atherosclerosis**  
Imo Hoefer - Universitair Medisch Centrum Utrecht, THE NETHERLANDS (10 min)
- Introduction to WP2 and new algorithms for targets selection**  
Ignat Drozdov - Bering Limited, UK (WP leader) (10 min)
- Validation of omics targets in patient cohorts**  
Gunilla Nordin Fredrikson / Harry Björkbacka - Lunds Universitet, SWEDEN (10 min)
- Which targets to select for validation?**  
Joint Discussion WP1 and WP2 - Discussion (60 min)
- 14.40-15.00 Coffee break
- 15.00-16.30 **WP3 Validation of novel targets for B cell responses with pro-atherogenic outcome**  
Chair: Marie Wikström Lindholm - Roche Innovation Center Copenhagen, DENMARK
- LNAs for targeting B cells and other inflammatory cells**  
Marie Wikström Lindholm - Roche Innovation Center Copenhagen, DENMARK (WP leader)(10 min)
- SiRNA platforms for B cell target screening: how to move from target screening**  
Federico Carbone - Università degli Studi di Genova, ITALY (10 min)
- Which targets to select for LNA studies?**  
Claudia Monaco - University of Oxford, UK (10 min)
- How to move from target screening to LNAs**  
Discussion (60 min)
- 17.00 City walk
- 19.00 Networking dinner

**Day 2: Tuesday, 4<sup>th</sup> October**

- 09.15-09.55 **Minisymposium: 4 young investigators presenting their research**  
Chairs: Claudia Monaco - University of Oxford, UK
- Circulating IgG4 levels predict for future cardiovascular manifestations in patients from the Athero Express biobank**  
Saskia De Jager - Universitair Medisch Centrum Utrecht, THE NETHERLANDS (15min)
- Pro-atherogenic ApoAI producing B cells**  
Francois Mach - Université de Genève, SWITZERLAND (15 min)
- 09.55-11.25 **WP4 Validation of targets related to the enhancements of Bregs**  
Chair: Stephen Malin - Karolinska Institutet, SWEDEN
- Introduction to WP and Master regulators of Bregs in humans and mice: results from omics studies**  
Paul Blair - University College London, UK (WP leader) (10 min)
- Old and new Athero-Bcell mice**  
Stephen Malin - Karolinska Institutet, SWEDEN (10min)
- Targeting B cells and inflammation in atherosclerosis using mouse and humanised models**  
Discussion (60 min)
- 10.30-10.45 *Coffee break*
- 10.45-11.30 **WP5&6**  
Riccardo Bertini - ALTA Ricerca e Sviluppo in Biotecnologie S.r.l.u., ITALY
- Which training activities?**  
Discussion (20 min)
- 11.30-12.30 **Discussion with the SAB member**  
Professor Esther Lutgens - Academisch Medisch Centrum bij de Universiteit van Amsterdam, THE NETHERLANDS
- 12.30-13.30 *Lunch*
- 13.30-15.00 **Steering committee**
- 15.00-15.30 *Coffee break*
- 15.30-17.00 **Revision work on the Scientific report (WP-based groups chaired by the WP leaders)**
- 17.00 *Departures*